tbuckley/cabot-search huggingface dataset:
Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults
Authors: Helen Ward, Graham S. Cooke, Christina Atchison, Matthew Whitaker, Joshua Elliott, Maya Moshe, Jonathan C Brown, Barnaby Flower, Anna Daunt, Kylie Ainslie, Deborah Ashby, Christl A. Donnelly, Steven Riley, Ara Darzi, Wendy Barclay, Paul Elliott
Journal: The Lancet Regional Health - Europe (2021)

The time-concentrated nature of the first wave of the COVID-19 epidemic in England in March and April 2020 provides a natural experiment to measure changes in antibody positivity at the population level before onset of the second wave and initiation of the vaccination programme. Three cross-sectional national surveys with non-overlapping random samples of the population in England undertaken between late June and September 2020 (REACT-2 study). 365,104 adults completed questionnaires and self-administered lateral flow immunoassay (LFIA) tests for IgG against SARS-CoV-2. Overall, 17,576 people had detectable antibodies, a prevalence of 4.9% (95% confidence intervals 4.9, 5.0) when adjusted for test characteristics and weighted to the adult population of England. The prevalence declined from 6.0% (5.8, 6.1), to 4.8% (4.7, 5.0) and 4.4% (4.3, 4.5), over the three rounds of the study a difference of -26.5% (-29.0, -23.8). The highest prevalence and smallest overall decline in positivity was in the youngest age group (18-24 years) at -14.9% (-21.6, -8.1), and lowest prevalence and largest decline in the oldest group (>74 years) at -39.0% (-50.8, -27.2). The decline from June to September 2020 was largest in those who did not report a history of COVID-19 at -64.0% (-75.6, -52.3), compared to -22.3% (-27.0, -17.7) in those with SARS-CoV-2 infection confirmed on PCR. A large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first wave. Widespread vaccination is needed to confer immunity and control the epidemic at population level. This work was funded by the Department of Health and Social Care in England.
Predictors of Cognitive Performance Among Infants Treated for Brain Tumors: Findings From a Multisite, Prospective, Longitudinal Trial
Authors: Jeanelle S. Ali, Jason M. Ashford, Michelle A. Swain, Lana L. Harder, Bonnie L. Carlson-Green, Jonathan M. Miller, Joanna Wallace, Ryan J. Kaner, Catherine A. Billups, Arzu Onar-Thomas, Thomas E. Merchant, Amar Gajjar, Heather M. Conklin
Journal: Journal of Clinical Oncology (2021)

PURPOSE Infants treated for CNS malignancies experience a significantly poorer response to treatment and are particularly at risk for neuropsychological deficits. The literature is limited and inconsistent regarding cognitive outcomes among this group. We investigated predictors of cognitive outcomes in children treated for brain tumors during infancy as part of a large, prospective, multisite, longitudinal trial. PATIENTS AND METHODS One hundred thirty-nine infants with a newly diagnosed CNS tumor were treated with chemotherapy, with or without focal proton or photon radiation therapy (RT). Cognitive assessments were conducted at baseline, 6 months, 1 year, and then annually for 5 years. The median length of follow-up was 816 days (26.8 months). Neurocognitive testing included assessment of intellectual functioning (intellectual quotient [IQ]), parent ratings of executive functioning and emotional and behavioral functioning, and socioeconomic status. RESULTS At baseline, IQ, parent-reported working memory, and parent-reported adaptive functioning were worse than normative expectations. Baseline cognitive difficulties were associated with younger age at diagnosis and lower socioeconomic status. Linear mixed models did not demonstrate a decline in IQ over time. There were increased parent-reported attention and executive problems over time. Increased concerns were related to supratentorial tumor location and CSF diversion. There were no differences in cognitive outcomes based on treatment exposure (chemotherapy-only v chemotherapy with RT and proton v photon focal RT). CONCLUSION Even before adjuvant therapy, young children with brain tumors experience cognitive difficulties that can affect quality of life. Changes in cognitive functioning over time were dependent on tumor location and surgical factors rather than adjuvant therapy. These findings may serve to guide treatment planning and indicate targets for cognitive monitoring and intervention.
PLIN2 IS AN AGE-RELATED BRIDGE BETWEEN OXIDATIVE STRESS AND METABOLISM-DEPENDENT INFLAMMATION IN CORONARY INSTABILITY
Authors: Francesco Canonico, Anna Severino, Chiara Pidone, Massimiliano Camilli, Stefano Migliaro, Ramona Vinci, Mattia Galli, Eugenia Pisano, Alessandra Arcudi, Alice Bonanni, Marianna Di Sario, Giulia Angelini, Daniela Pedicino, Rocco Montone, Giampaolo Niccoli, Giovanna Liuzzo, Filippo Crea, Domenico D'Amario
Journal: Journal of the American College of Cardiology (2021)
Hydrodynamic Mixing Tunes the Stiffness of Proteoglycan‐Mimicking Physical Hydrogels
Authors: James P. Warren, Danielle E. Miles, Nikil Kapur, Ruth K. Wilcox, Paul A. Beales
Journal: Advanced Healthcare Materials (2021)

Self-assembling hydrogels are promising materials for regenerative medicine and tissue engineering. However, designing hydrogels that replicate the 3-4 order of magnitude variation in soft tissue mechanics remains a major challenge. Here hybrid hydrogels are investigated formed from short self-assembling β-fibril peptides, and the glycosaminoglycan chondroitin sulfate (CS), chosen to replicate physical aspects of proteoglycans, specifically natural aggrecan, which provides structural mechanics to soft tissues. Varying the peptide:CS compositional ratio (1:2, 1:10, or 1:20) can tune the mechanics of the gel by one to two orders of magnitude. In addition, it is demonstrated that at any fixed composition, the gel shear modulus can be tuned over approximately two orders of magnitude through varying the initial vortex mixing time. This tuneability arises due to changes in the mesoscale structure of the gel network (fibril width, length, and connectivity), giving rise to both shear-thickening and shear-thinning behavior. The resulting hydrogels range in shear elastic moduli from 0.14 to 220 kPa, mimicking the mechanical variability in a range of soft tissues. The high degree of discrete tuneability of composition and mechanics in these hydrogels makes them particularly promising for matching the chemical and mechanical requirements of different applications in tissue engineering and regenerative medicine.
Questions About DNR Orders
Authors: David Leivers
Journal: JAMA (1991)

<h3>To the Editor.</h3> —The recent update of the cardiopulmonary resuscitation guidelines<sup>1</sup>and editorial comment<sup>2</sup>are welcome as further developments in this complicated and evolving area. However, many specific problems were not addressed. Truog<sup>3</sup>reviewed the question of the status of DNR orders in patients undergoing surgery and anesthesia. For anesthesiologists, there are special and frequently conflicting aspects of providing care during palliative surgery. The following case highlights this dilemma: A 54-year-old man with endstage amyotrophic lateral sclerosis presented for gastrostomy. He was fully alert but confined to a wheelchair. He lived at home with his caring wife. His profound weakness did not permit coordinated swallowing, and his decline was being accelerated by malnutrition. Respiratory reserve was negligible with PaO<sub>2</sub>of 56 mm Hg breathing air and PaCO<sub>2</sub>of 54 mm Hg. In a discussion prior to the procedure, the patient and his wife revealed an
The curious incident of the cast in the airway
Authors: Yueqi Ge, Emily C Bartlett, Thomas Semple, Alexandra Rice, Anand Shah, Elisabetta A Renzoni
Journal: Thorax (2021)

A 52-year-old man presented with progressive dyspnoea and productive cough over 4 months. He was in type 2 respiratory failure (pO2 7.99 kPa/60 mm Hg; pCO2 9.32 kPa/70 mm Hg) with fluid overload and was started on non-invasive ventilation and intravenous diuresis in intensive care. Physical examination was significant for his short neck, small jaw and body mass index of 50. He was expectorating thick branching sputum, and bronchial casts were retrieved on bronchoscopy (figure 1A).



Figure 1 
(A) Image of bronchial cast removed during bronchoscopy. (B) Section of laminated proteinaceous cast material (black arrow) with admixed small lymphocytes and foamy macrophages (black arrow) with scale bar (H&E ×40).



A chest CT showed endobronchial material and extensive bilateral ground glass opacification (figure 2A,B). Sputum cultures were negative but biochemical analysis revealed high triglycerides. Histopathological analysis revealed a fibrinous sample with foamy macrophages, occasional eosinophils and mildly atypical epithelioid cells (figure …
Abstract 16883: Validation of a Deep Neural Network Electrocardiographic-Age as a Mortality Predictor: The CODE Study
Authors: Gabriela Paixao, Emilly M Lima, Antonio H Ribeiro, Paulo R Gomes, Derick Oliveira, Marcelo M Pinto Junior, Ester Sabino, Sandhi Barreto, Luana Giatti, Paulo A Andrade Lotufo, Bruce Duncan, Wagner Meira Junior, Thomas Schon, Antonio L Ribeiro
Journal: Circulation (2020)

Introduction: Aging affects the electrocardiogram (ECG) with a higher incidence of abnormalities in older patients. ECG-age can be predicted by artificial intelligence (AI) and can be used as a measure of cardiovascular health. Hypothesis: ECG-age predicted by AI is a risk factor for overall mortality. Methods: The Clinical Outcomes in Digital Electrocardiography (CODE) study is a retrospective cohort with a mean follow-up of 3.67 years.The dataset consists of Brazilian patients, mainly from primary care centers. Two established cohorts, ELSA-Brasil, of Brazilian public servants, and SaMi-Trop, of Chagas disease patients, were used for external validation. 2,322,513 ECGs from 1,558,421 patients over 16 years old that underwent an ECG from 2010 to 2017 were included. A deep convolutional neural network was trained in order to predict the age of the patient based solely on ECG 12-lead tracings. The ECG database was split into 85-15% training and test datasets, respectively. Death was ascertained using probabilistic linkage with Brazil′s mortality information data. The Cox regression model, adjusted by age and sex, was used for statistical analysis. The model was validated in two cohorts: ELSA-Brasil (n=14,263) and SaMi-Trop (n=1,631). Results: he mean predicted ECG-age was 52.0 years (±18.7) with a mean absolute error of 8.38 (±7.0) years. Patients with ECG-age &gt;8y older than chronological age had higher mortality rate (HR 1.79, 95%CI 1.69-1.90; p&lt;0.001), whereas those ECG-age &gt;8y younger than chronological age were associated with a lower mortality rate (HR 0.78, 95%CI 0.74-0.83; p&lt;0.001). These results were similar in ELSA-Brasil and SaMi-Trop external validation cohorts (HR 1.75, 95%CI 1.35-2.27; p&lt;0.001;HR 2.42, 95%CI 1.53-3.83; p&lt;0.001 for &gt;8y difference, retrospectively; HR 0.74, 95%CI 0.63-0.88; p&lt;0.001;HR 0.89, 95%CI 0.52-1.54; p=0.68 for &lt;8y difference, respectively). Conclusions: ECG-age, predicted by AI, can be useful as a tool for risk stratification of mortality.
STROKE/SYSTEMIC EMBOLISM, VASCULAR DEATH AND BLEEDING IN NONVALVULAR ATRIAL FIRBILLATION PATIENTS WITH TYPE 2 DIABETES RECEIVING RIVAROXABAN OR WARFARIN
Authors: Olivia Costa, Christopher W. Brescia, Burcu Vardar, Khaled Abdelgawwad, Nitesh Sood, Craig I. Coleman
Journal: Journal of the American College of Cardiology (2021)
Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy
Authors: Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, Michael J. Sorich
Journal: Journal of the National Comprehensive Cancer Network (2021)

Background: Concomitant use of proton pump inhibitors (PPIs) may negatively affect the efficacy of anticancer drugs such as fluoropyrimidines in patients with colorectal cancer (CRC). The primary objective of this study was to assess whether there is an association between concomitant PPI use and survival outcomes in patients with CRC treated with a fluoropyrimidine-based chemotherapy. Patients and Methods: A secondary analysis of 6 randomized controlled clinical trials in patients with advanced CRC was conducted using individual patient data through data-sharing platforms. The outcome measures were progression-free survival and overall survival in PPI users and nonusers. Subgroup analysis included the type of chemotherapy, capecitabine versus 5-FU, line of therapy, and addition of a vascular endothelial growth factor receptor inhibitor. Overall pooled hazard ratios (HRs) with 95% confidence intervals were calculated using a random effects model. Results: A total of 5,594 patients with advanced CRC across 6 trials and 11 trial arms were included; 902 patients were receiving a PPI at trial entry and initiation of chemotherapy. PPI use was significantly associated with worse overall survival (pooled HR, 1.20; 95% CI, 1.03–1.40; P =.02; I 2 for heterogeneity = 69%) and progression-free survival (overall pooled HR, 1.20; 95% CI, 1.05–1.37; P =.009; I 2 = 65%) after adjusting for clinical covariates. Furthermore, the association between concomitant PPI use and survival outcomes was similar across most treatment subgroups. Conclusions: We speculate that alterations in the gut microbiome, altered immune milieu within the tumor, and interactions through transporters are potential mechanisms behind this association between PPI use and chemotherapy in patients with CRC, which warrant further study. Concomitant use of PPIs is associated with worse survival outcomes in patients with CRC treated with fluoropyrimidine-based chemotherapy. Clinicians should cautiously consider the concomitant use of PPIs in such patients.
PREVALENCE OF NON-PV TRIGGERS IN HIV-POSITIVE PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING CATHETER ABLATION
Authors: Sanghamitra Mohanty, Chintan Trivedi, Carola Gianni, Domenico Della Rocca, Bryan MacDonald, Angel Mayedo, John Burkhardt, G. Gallinghouse, Amin Al-Ahmad, Rodney Horton, Luigi Di Biase, Andrea Natale
Journal: Journal of the American College of Cardiology (2021)
RELATIONSHIPS BETWEEN MYOCARDIAL INJURY, INDEX HOSPITALIZATION CHARACTERISTICS, AND LONGER-TERM OUTCOMES IN SARS-COV-2 INFECTION
Authors: Brittany Weber, Hasan Siddiqi, Jefferson Vieira, Guohai Zhou, Andy Kim, Henry Rutherford, Xhoi Mitre, Monica Feeley, Karina Oganezova, Anubodh Varshney, Ankeet Bhatt, Victor Nauffal, Deepak Atri, Ron Blankstein, Marcelo Di Carli, Lindsey Baden, Deepak Bhatt, Ann Woolley
Journal: Journal of the American College of Cardiology (2021)
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
Authors: Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto
Journal: Clinical Cancer Research (2021)

MORAb-202, an antibody-drug conjugate containing farletuzumab and eribulin with a cathepsin-B cleavable linker, targets folate receptor α (FRα)-expressing tumor cells. The primary objective of this first-in-human study was to evaluate the safety and tolerability of MORAb-202 in patients with solid tumors.Patients ≥20 years with adequate organ function and FRα-positive solid tumors who failed to respond to standard therapy were eligible. Patients received MORAb-202 intravenously at doses of 0.3 to 1.2 mg/kg once every three weeks. Endpoints included dose-limiting toxicities, safety, tumor responses, pharmacokinetics, and pharmacodynamics.NCT03386942 (ClinicalTrials.gov).Between November 28, 2017 and June 4, 2019, 22 patients (median age, 58.0 years) with advanced solid tumors were enrolled. Treatment-emergent adverse events occurred in 21 (95%) patients, with leukopenia and neutropenia in 10 (45%) patients each. One patient (0.9 mg/kg cohort) experienced two grade 3 dose-limiting toxicities: serum alanine aminotransferase and γ-glutamyl transferase increases. Following review by an independent adjudication committee, grade 1/2 interstitial lung disease thought to be related to MORAb-202 was identified in five (23%) patients. Complete response, partial response, and stable disease were observed in one, nine, and eight patients, respectively. The normalized predose serum FRα tended to be positively correlated with the maximum tumor shrinkage (R2 = 0.2379; P = 0.0291).The MTD of MORAb-202 was not reached. MORAb-202 demonstrated promising antitumor activity in FRα-positive solid tumors and was generally well-tolerated at the tested doses. Further investigations are required to establish appropriate dosage and clinical utility of MORAb-202.
B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis
Authors: Hiroko Numajiri, Ai Kuzumi, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki‐Ogawa, Yoshihide Asano, Yutaka Kazoe, Kazuma Mawatari, Takehiko Kitamori, Ayumi Yoshizaki, Shinichi Sato
Journal: Arthritis & Rheumatology (2021)

We undertook this study to investigate the effect of B cell depletion on fibrosis in systemic sclerosis (SSc) and its mechanism of action.Mice with bleomycin-induced SSc (BLM-SSc) were treated with anti-CD20 antibody, and skin and lung fibrosis were histopathologically evaluated. T cells and macrophages were cocultured with B cells, and the effect of B cells on their differentiation was assessed by flow cytometry. We also cocultured B cells and monocytes from SSc patients and analyzed the correlation between fibrosis and profibrotic macrophage induction by B cells.B cell depletion inhibited fibrosis in mice with BLM-SSc. B cells from mice with BLM-SSc increased proinflammatory cytokine-producing T cells in coculture. In mice with BLM-SSc, B cell depletion before BLM treatment (pre-depletion) inhibited fibrosis more strongly than B cell depletion after BLM treatment (post-depletion) (P < 0.01). However, the frequencies of proinflammatory T cells were lower in the post-depletion group than in the pre-depletion group. This discrepancy suggests that the effect of B cell depletion on fibrosis cannot be explained by its effect on T cell differentiation. On the other hand, profibrotic macrophages were markedly decreased in the pre-depletion group compared to the post-depletion group (P < 0.05). Furthermore, B cells from mice with BLM-SSc increased profibrotic macrophage differentiation in coculture (P < 0.05). In SSc patients, the extent of profibrotic macrophage induction by B cells correlated with the severity of fibrosis (P < 0.0005).These findings suggest that B cell depletion inhibits tissue fibrosis via suppression of profibrotic macrophage differentiation in mice with BLM-SSc, providing a new rationale for B cell depletion therapy in SSc.
SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIAL
Authors: Alexandra J. Lansky, Shigeru Saito, Michael Curtis, Dean Kereiakes, Andreas Baumbach, Barry Bertolet, James Zidar, Brent McLaurin, Nabil Dib, Pieter Smits, Victor Alfonso Jimenez Diaz, Angel Cequier, Sjoerd Hofma, Cody Pietras, Stephan Windecker, Martin Leon
Journal: Journal of the American College of Cardiology (2021)
INTERNATIONAL EVALUATION OF WEAKLY-SUPERVISED AI-MODEL FOR CARDIAC ALLOGRAFT REJECTION SCREENING
Authors: Jana Lipkova, Tiffany Y. Chen, Ming Y. Lu, Maha Shady, Mane Williams, Jingwen Wang, Richard N. Mitchell, Mehmet Turan, Gulfize Coskun, Derya Demir, Deniz Nart, Funda Y. Barbet, Yara Banz, Katja E. Odening, Faisal Mahmood
Journal: Journal of the American College of Cardiology (2021)
EXOSOME MEDIATED CARDIOPROTECTION IN ACUTE MYOCARDIAL INFARCTION
Authors: Christopher Livia, Michael Sabbah, Arvin Forghanian-Arani, Shivaram Poigai Arunachalam, Tyler Rolland, Timothy Peterson, Tyra Witt, Mary Nagel, Andre Terzic, Atta Behfar
Journal: Journal of the American College of Cardiology (2021)
Response to: ‘Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’’ by Roongta et al
Authors: Veerle F A M Derksen, Diane van der Woude
Journal: Annals of the Rheumatic Diseases (2021)

We thank Roongta et al 1 for the interest taken in our work and for bringing this interesting case of seropositive rheumatoid arthritis (RA) after COVID-19 to the attention. They describe a patient who developed polyarthritis after proven SARS-CoV-2 infection, with seroconversion for both rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) between 2 weeks and 6 months after infection. This raises the question whether seroconversion (becoming seropositive for ACPA and RF) might occur more often after COVID-19.

In our study, three out of five patients presenting with polyarthritis post-COVID were already autoantibody positive at first presentation to the rheumatologist, on average 8.3 weeks after COVID-19.2 Unfortunately, there was no serum available from the time before COVID-19 or from timepoints between SARS-CoV-2 infection and presentation to the rheumatologist, precluding any investigation into seroconversion after COVID-19 in these patients. However, detailed investigations into the characteristics of their ACPA response revealed the presence of multiple ACPA isotypes …
TREND OF HEART FAILURE READMISSION PREVENTION IN REMOTE DIELECTRIC SENSING (REDS) MONITORING- A META-ANALYSIS
Authors: Yasar Sattar, Abdul-Rahman M. Suleiman, Tanveer Mir, Waqas Ullah, Mohamed Zghouzi, Junaid Arshad, Ghaith Alhatemi, Homam Moussa Pacha, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2021)
ABSOLUTE CUMULATIVE DOSE NOT CUMULATIVE DOSE INDEXED BY BSA PREDICTS DOXORUBICIN-INDUCED SUBCLINICAL CARDIOTOXICITY
Authors: Hua Zhong, Bhoomi Mehrotra, Kristine Bond, Sherly Jacob-Perez, Nathaniel Reichek, Haoyi Zheng
Journal: Journal of the American College of Cardiology (2021)
LUNG INJURY AND FUNCTIONAL CAPACITY POST-SARS-COV-2 INFECTION
Authors: Francesco Bandera, Eleonora Alfonzetti, Mattia Mazzucca, Greta Ghizzardi, Francesco Secchi, Francesco Sardanelli, Massimiliano M Corsi-Romanelli, Marco Guazzi
Journal: Journal of the American College of Cardiology (2021)
MACHINE LEARNING FOR PREDICTING ANGIOGRAPHIC PRESENCE OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE IN YOUNG ADULTS
Authors: Maryam Saleem, Naveena Yanamala, Irfan Zeb, Brijesh Patel, Heenaben Patel, Abhiram Challa, Partho Sengupta
Journal: Journal of the American College of Cardiology (2021)
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
Authors: Benaya Rozen-Zvi, Dafna Yahav, Timna Agur, Boris Zingerman, Haim Ben-Zvi, Alaa Atamna, Noam Tau, Tiki Mashraki, Eviatar Nesher, Ruth Rahamimov
Journal: Clinical Microbiology and Infection (2021)
PREDICTORS OF PERMANENT PACEMAKER IMPLANTATION IN PATIENTS UNDERGOING TRANSCATHER AORTIC VALVE REPLACEMENT - A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Waqas Ullah, Salman Zahid, Ramsha Zaidi, Shujaul Haq, Sohaib Roomi, Deepika Sarvepalli, Maryam Mukhtar, Atif Khan, Smitha Narayana Gowda, Nicholas Ruggiero, Alec Vishnevsky, David Fischman
Journal: Journal of the American College of Cardiology (2021)
EFFECT OF YOGA ON CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH VASOVAGAL SYNCOPE- A RANDOMISED CONTROL TRIAL
Authors: Venkatakrishnan Ramakumar, Gautam Sharma, Nitish Naik, Mohammed Sharique, Aman Agarwal, Deepti Kailath, Raghav Bansal, Anita Saxena
Journal: Journal of the American College of Cardiology (2021)